Sarepta (SRPT) Q1 2026 earnings review
Profitable on Paper, But Flagship Franchise Still Searching for a Bottom
Sarepta posted a massive $358.4 million GAAP operating profit in Q1 2026, but this headline number creates a dangerous optical illusion. The profitability was entirely driven by $400.3 million in collaboration revenue—primarily a $365 million non-cash recognition from Roche declining a program option. Stripping this away reveals a core business under severe stress: net product revenue plunged 46% YoY to $330.5 million. The primary culprit is ELEVIDYS, which continues to suffer the lingering effects of the mid-2025 label restriction for non-ambulatory patients. ELEVIDYS sales decelerated sequentially to $102.0 million, marking the fourth consecutive quarter of decline from its Q1 2025 peak of $375 million. While management claims the commercial portfolio 'has begun to stabilize,' the data confirms that a true bottom has not yet materialized.
🐂 Bull Case
Initial Phase 1/2 data for SRP-1001 (FSHD1) and SRP-1003 (DM1) showed dose-dependent exposure and early biomarker effects without dose-limiting safety, validating the new platform.
Dosing for Cohort 8 of the ENDEAVOR study is officially underway using a prophylactic sirolimus regimen, providing a concrete regulatory pathway to potentially reopen the non-ambulatory market for ELEVIDYS.
🐻 Bear Case
Despite management declaring 2026 a 'reset year' aimed at stabilizing demand, ELEVIDYS sales fell sequentially to $102 million. Educational initiatives have yet to show measurable financial impact.
Total product revenue of $330.5M failed to cover core operating costs (Cost of Sales + R&D + SG&A) of $371.6M. The company relies entirely on one-time milestone payments to report a profit.
⚖️ Verdict: 🔴
Bearish. The massive GAAP profit is a low-quality accounting outcome driven by partner milestones. The foundational story—ELEVIDYS adoption—is still severely broken, with sales decelerating sequentially and remaining nearly 75% below their peak.
Key Themes
Accounting Optical Illusion: Operations Contradict Profit Narrative
Management stated they remain in a 'position of financial strength, with positive earnings.' However, the specific data contradicts the health of ongoing operations. The $358.4M GAAP operating income was entirely manufactured by $400.3M in collaboration revenue ($365M non-cash from Roche declining an option, $40M milestone for Japan dosing). Total product revenues of $330.5M were insufficient to cover the $371.6M combined cost of sales ($108.8M), R&D ($154.0M), and SG&A ($108.9M). Without external partner subsidies, the core commercial enterprise is operating at a deficit.
ELEVIDYS Trajectory Still Decelerating
The highly anticipated turnaround for ELEVIDYS remains elusive. Sales fell sequentially from $110.4M in 25Q4 to $102.0M in 26Q1. While the YoY comparison (-73% from 25Q1) is distorted by the mid-2025 label restriction removing non-ambulatory patients, the sequential decline indicates that the new commercial initiatives and expanded field engagement strategies have not yet stabilized adoption within the approved ambulatory population.
siRNA Pipeline Validation
A crucial pivot point for Sarepta's future value proposition arrived with early Phase 1/2 data for the siRNA portfolio. SRP-1001 for FSHD1 and SRP-1003 for DM1 demonstrated dose-dependent drug exposure, early biomarker effects, and favorable tolerability with no dose-limiting safety signals. This provides vital early validation for the αvβ6 integrin-targeted delivery platform, which management hopes will define the 'next era' of the company beyond Duchenne.
PMO Franchise Decelerating Sequentially
The PMO legacy franchise (EXONDYS 51, VYONDYS 53, AMONDYS 45), which management has repeatedly leaned on as the stable financial bedrock, showed unexpected weakness. Revenue dropped sequentially to $228.6M from $259.2M in 25Q4. While the YoY comparison ($237M in 25Q1) shows slight erosion, the QoQ drop raises concerns about potential competitive pressure or accelerating cannibalization from ELEVIDYS.
ENDEAVOR Cohort 8 Advances
Execution on the clinical pathway to recapture the non-ambulatory market is progressing. Screening and enrollment for approximately 25 patients in Cohort 8 of the ENDEAVOR study is underway, and as of April 2026, dosing has commenced. This cohort evaluates prophylactic sirolimus to mitigate acute liver injury risks. Positive data here is the absolute prerequisite to expanding the ELEVIDYS label back to its original addressable market.
PMO Regulatory Pathway Progress
In April 2026, Sarepta submitted sNDAs to convert AMONDYS 45 and VYONDYS 53 from accelerated to traditional approvals. This submission relies heavily on 'substantial real-world evidence' to counter the previous failure of the ESSENCE confirmatory study to reach statistical significance. Achieving traditional approval would significantly de-risk the ~$900M annual baseline revenue stream.
Other KPIs
GAAP R&D plummeted $619.4M YoY. However, this is largely an artifact of the prior year period containing a massive $583.6 million upfront license fee paid to Arrowhead Pharmaceuticals. Non-GAAP R&D expenses, which strip out stock-based comp and depreciation, were $137.5M, down significantly from previous periods due to the July 2025 pipeline reprioritization and LGMD program pauses.
Reversing. Cash dropped significantly from $953.8M at the end of FY 2025. Management notes that underlying operations were cash flow positive when excluding planned Arrowhead collaboration payments ($50M paid in Q1), but the absolute decline of $205M in a single quarter underscores the cash burn required to sustain operations and debt service when product revenues falter.
Guidance
Stable outlook, but implies a required acceleration. With Q1 net product revenue at $330.5M, the current run-rate is roughly $1.32B. However, because Q1 included no sequential growth for ELEVIDYS, hitting the upper half of this guidance will demand a noticeable inflection point and re-acceleration of ELEVIDYS demand in the second half of the year.
Stable. The combined Q1 run rate for Non-GAAP R&D ($137.5M) and Non-GAAP SG&A ($86.1M) totals $223.6M. Annualized, this equals ~$894M, putting the company perfectly on track near the high end of its guidance range, demonstrating that the harsh cost-cutting and workforce reductions initiated in mid-2025 are structurally holding.
Key Questions
ELEVIDYS Trajectory Confidence
ELEVIDYS revenue declined sequentially from Q4 to Q1. What specific leading indicators—such as new start forms or pre-authorization approvals—give you the confidence to reiterate the $1.2B to $1.4B full-year guidance range?
PMO Franchise Erosion
PMO revenues dropped notably from $259M in Q4 to $228M this quarter. Is this sequential decline a product of typical Q1 administrative friction, direct cannibalization from ELEVIDYS, or a new baseline?
Cash Flow Reconciliation
You mentioned operations were cash flow positive excluding the Arrowhead payment, yet total cash and investments declined by $205M sequentially. Can you walk us through the primary working capital or debt service drains that drove this substantial drop?